Core Insights - Eli Lilly and Company is investing over $1 billion (approximately ₹8,900 crore) to establish new contract manufacturing facilities in India, marking one of the largest investments in the Indian pharma sector in recent years [3] - The investment decision was influenced by Telangana's favorable ecosystem, including skilled manpower, infrastructure, and government support, despite competition from other states [1][3] - The new hub in Hyderabad will enhance Eli Lilly's manufacturing and supply capabilities, supporting its evolving portfolio and leveraging India's talent pool [1][3] Investment and Expansion - Since 2020, Eli Lilly has committed over $55 billion globally to build, expand, and acquire facilities [2][3] - The new facilities will focus on developing and manufacturing medicines for conditions such as diabetes, obesity, Alzheimer's disease, cancer, and autoimmune diseases [2][3] - The company plans to begin immediate recruitment for various roles at the new hub, including engineers, chemists, and quality control professionals [2][3] Job Creation and Local Impact - The investment will not only expand Eli Lilly's manufacturing and global medicine supply capacity in Hyderabad but also create job opportunities for local youth [2][3] - The Telangana government confirmed that all investments will be made entirely within the state [2][3]

Core Insights - Eli Lilly will invest over $1 billion in new contract manufacturing facilities in India, establishing a new manufacturing and quality hub in Hyderabad [2][3] - The investment aims to enhance Lilly's supply capabilities and leverage India's skilled talent pool to support global manufacturing growth [3][4] - Since 2020, Lilly has committed over $55 billion to build, expand, and acquire facilities globally, focusing on new medicines for diabetes, obesity, Alzheimer's, cancer, and autoimmune conditions [2][3] Company Strategy - The new hub in Hyderabad will provide advanced technical capabilities and oversight for Lilly's contract manufacturing network across India [2][3] - Immediate recruitment will begin for various roles, including engineers, chemists, analytical scientists, and quality control professionals [2][3] - The investment reflects Lilly's confidence in India as a key location for capability building within its global network [3][4] Regional Impact - Telangana's officials view Lilly's expansion as a validation of the state's emergence as a global healthcare innovation hub [4] - The state's focus on technology-driven infrastructure and ease of doing business is attracting global leaders, particularly in the life sciences sector [4] - Lilly's existing commercial site in Gurugram and specialized sites in Bengaluru and Hyderabad support global innovation and are being reinforced through strategic investments [4]

Group 1 - Biogen Inc. is considered one of the best drug stocks to buy currently, with a Buy rating and a price target of $220.00 set by Canaccord Genuity [1] - In fiscal Q2 2025, Biogen reported total revenue of $2.6 billion, reflecting a 7% year-over-year increase [2] - The GAAP diluted EPS for the quarter was $4.33, up 8% year-over-year, while the non-GAAP diluted EPS rose 4% year-over-year to $5.47 [2] Group 2 - Biogen's medicine portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) [3]